Eisai’s E6201 is a dual-targeted FLT3 and MEK inhibitor, which has completed a PhaseI clinical trial showing preliminary antitumor activity and an acceptable safety profile.
Building on a strong scientific rationale supported by recent preclinical data, BSC company will undertake a clinical proof of concept (PoC) trial in the high unmet need FLT3 mutated AML patients.
As part of the deal, BSC has worldwide rights to develop and commercialize E6201 for all Oncology indications.
Boston Strategics president Eita Kitayama said this is a critical milestone for the company to validate its concept to move drug development programs forward by increasing the Probability of Success (PoS) and sharing risks with key strategic partners.
"Eisai recognized the value of this approach and entrusted BSC with the development of E6201 for cancer indications to build on the foundation of this new platform," Kitayama said.
"At BSC, we are deeply committed to proving that our innovative approaches can deliver breakthrough therapies with industry benchmark-beating timelines, quality, and financial investments, thus limiting the ever increasing costs of pharmaceutical innovation and development."